Partnering with Alexion

The future is upon us and our dedicated team is ready to partner with you to reach your drug development milestones. By partnering with Alexion, we can accelerate the delivery of lifesaving therapies to patients.

Have a question? Want to brainstorm? Let Tara Reilly know you’re ready to collaborate and resolve your drug development challenges.

Contact Tara

scientist looking in microscope

Shared Alexion Resources

3d render of DNA on red background.

Approaches to Rare Disease Studies

Platforms such as high-throughput screening (HTS), cell-based assays, and research models can be designed to mimic specific diseases using CRISPR and stem cell technology, providing more disease-relevant data for safety studies and eventual translation to the clinic.

What Can We Offer You?

Pyramidal neurons are found in certain areas of the brain including the cerebral cortex, the hippocampus, and the amygdala.

Enter the New Era of CNS

CNS drug discovery isn't for the faint of heart. We can't be deterred by clinical failures, but it's clear that some approaches aren't working. It's time to building upon the foundations of our current research and start over. Get ready to explore new tools and techniques to generate data that drives confident decisions in the earliest stages of development.

Explore our Microsite

X-ray image of chest

SOT Safety Pharmacology Poster Presentation

This study demonstrated both the comprehensive electrical evaluation of the heart and repeatability of the electrophysiology testing protocol for arrhythmia generation, and for safety evaluation of new chemical and biological entities.

Watch Brian Roche’s Presentation

Neon brain. Cpu. Circuit board. Abstract technology background. Vector

Are You Ready for the Digital Pathology Revolution?

The digitization of pathology data for diagnostic and decision support, peer review, and computer-based analytics, or digital pathology, is here. Potentially more objective, accurate, and faster than traditional microscopy, the technology is changing our workflow. Our pathology experts have presented a three-part webinar series so you can discover platforms, learn best practices, and put a plan in place to harness the power of digital analysis in your preclinical programs.

Watch Now

Considerations for Clinical Sample Analysis

With well-established experience in sample management and kit assembly for Phase I through III clinical trials worldwide, we produce over 1,300 sample kits per month. In many cases, our scientists are involved at the start of nonclinical programs and stay on through subsequent testing, collaborating as part of the clinical study team. This approach results in robust and reliable methods for clinical sample analysis, which, when combined with data management, enables us to provide high-quality, on-time clinical data to support drug approval.

In addition to clinical bioanalysis, we also offer extensive biomarker testing services, including clinical efficacy/PD biomarkers, which are crucial for confirming target engagement and improving your chances of moving to Phase III. Through our CLIA certification, we can also develop novel biomarkers for use in diagnostic testing, post-market patient safety monitoring, and companion diagnostic testing.

Pharmacodynamic (PD) Biomarkers Video

Russell Garland, our Group Leader of Analytical Services, discusses the advantages of using clinical efficacy/PD biomarkers.

uncapped medicine bottle

Who Should You Trust to Run Your Product Release Testing?

With over 20 years’ experience supporting method development, phase-appropriate validation, and release testing, let us handle your routine testing so you can focus on more pressing matters. We provide a comprehensive package of GMP product release services, from addressing biosafety concerns and analyzing potency using suitable bioassays, to determining purity and other biochemical characteristics. Our assays follow US Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese (JP) guidelines.

View Our Program

image of a virus

Preserve the Safety of Your Biologics

Viral clearance studies are essential to ensure product safety. With laboratories in Europe and the US, we have the technical and regulatory expertise to ensure studies comply with relevant guidelines (e.g., EU, US, Japan, and WHO, including ICH QSA). Regulatory authorities have accepted all of the viral clearance studies we’ve ever submitted to them for review. We can support a range of products, including tissue- and blood-derived products, vaccines, and medical devices.

Learn more about viral clearance studies by attending our upcoming 5th Annual Viral Safety and Viral Clearance Summit in October. Join thought leaders and experts as they share the latest trends, techniques, and regulatory requirements in the industry.

Pre-register Today

Your Dedicated Team